Literature DB >> 3883425

Breast lesions examined by digital angiography. Work in progress.

L V Ackerman, A C Watt, P Shetty, M J Flynn, M Burke, A Kambouris, G Fine, S Wilderman.   

Abstract

Differentiation of benign from malignant lesions in screening for breast cancer is usually arrived at via surgical biopsy, an invasive and costly procedure. Digital subtraction angiography (DSA) of the breast is a less invasive procedure. DSA imaging patterns from 22 patients with malignant and benign lesions were compared with surgical biopsy findings. DSA examinations were performed with the breast in an immobilization device and contrast medium was injected into the superior vena cava. Images were produced with a low kilovoltage (50 kVp) to enhance contrast, and a technique yielding an average dose to the breast of less than 2 rad (0.02 Gy) was used. Preliminary clinical results demonstrate the potential of DSA for differentiation of benign and malignant lesions and justify further investigations of its use as an alternative to surgical biopsy.

Entities:  

Mesh:

Year:  1985        PMID: 3883425     DOI: 10.1148/radiology.155.1.3883425

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  3 in total

1.  Initial clinical experience with contrast-enhanced digital breast tomosynthesis.

Authors:  Sara C Chen; Ann-Katherine Carton; Michael Albert; Emily F Conant; Mitchell D Schnall; Andrew D A Maidment
Journal:  Acad Radiol       Date:  2007-02       Impact factor: 3.173

2.  Quantitative analysis of enhanced malignant and benign lesions on contrast-enhanced spectral mammography.

Authors:  Chih-Ying Deng; Yu-Hsiang Juan; Yun-Chung Cheung; Yu-Ching Lin; Yung-Feng Lo; GiGin Lin; Shin-Cheh Chen; Shu-Hang Ng
Journal:  Br J Radiol       Date:  2018-02-27       Impact factor: 3.039

Review 3.  Contrast-enhanced mammography: past, present, and future.

Authors:  Julie Sogani; Victoria L Mango; Delia Keating; Janice S Sung; Maxine S Jochelson
Journal:  Clin Imaging       Date:  2020-09-19       Impact factor: 1.605

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.